NGM Biopharmaceuticals Inc (DELISTED) (NGM:DL)

1.54 0.00 (0.00%) USD  |  NASDAQ  |  Apr 05, 16:00
More

NGM Biopharmaceuticals Cash from Operations (Quarterly): -22.96M for Dec. 31, 2023

Cash from Operations (Quarterly) Chart

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2018. Upgrade now.
Date Value
December 31, 2023 -22.96M
September 30, 2023 -27.16M
June 30, 2023 -40.25M
March 31, 2023 -41.83M
December 31, 2022 -30.40M
September 30, 2022 -28.15M
June 30, 2022 -50.15M
March 31, 2022 -35.74M
December 31, 2021 -18.34M
September 30, 2021 -9.359M
June 30, 2021 -23.31M
March 31, 2021 -22.22M
Date Value
December 31, 2020 -20.04M
September 30, 2020 -25.16M
June 30, 2020 -19.18M
March 31, 2020 -19.11M
December 31, 2019 -14.60M
September 30, 2019 -6.696M
June 30, 2019 -7.777M
March 31, 2019 -12.10M
December 31, 2018 7.008M
September 30, 2018 -5.851M
June 30, 2018 -4.289M
March 31, 2018 -4.465M

Cash From Operations Definition

Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

-50.15M
Minimum
Jun 2022
-6.696M
Maximum
Sep 2019
-24.34M
Average
-22.96M
Median
Dec 2023

Cash from Operations (Quarterly) Benchmarks

Catalent Inc 12.00M
AIM ImmunoTech Inc -4.815M
Perspective Therapeutics Inc 13.85M
Protalix BioTherapeutics Inc 4.188M
Armata Pharmaceuticals Inc -10.58M

Cash from Operations (Quarterly) Related Metrics

Cash from Investing (Quarterly) 27.19M
Cash from Financing (Quarterly) 0.111M
Free Cash Flow -133.45M
Free Cash Flow Per Share (Quarterly) -0.2796
Free Cash Flow to Equity (Quarterly) -23.15M
Free Cash Flow Yield -105.0%